| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 04/24/2008 | WO2008046757A1 Aminomethyl-4-imidazoles |
| 04/24/2008 | WO2008046756A1 Aminomethyl-2-imidazoles with affinity with the trace amine associated receptors |
| 04/24/2008 | WO2008046582A1 Substituted tetrahydropyrrolopyrazine compounds having affinity with the kcnq2/3 k+ channel and use thereof in medicaments |
| 04/24/2008 | WO2008046581A2 Substituted tetrahydropyrrolopyrazine compounds and use thereof in medicaments |
| 04/24/2008 | WO2008046228A1 Compounds for stimulating p-glycoprotein function and uses thereof |
| 04/24/2008 | WO2008046149A1 Herbal compositions for the prevention or treatment of restless leg syndrome |
| 04/24/2008 | WO2008046135A1 Novel anxiolytic compounds |
| 04/24/2008 | WO2008021518A3 Crystalline forms of tiagabine hydrochloride and processes for the preparation of amorphous tiagabine hydrochloride |
| 04/24/2008 | WO2008006979B1 Process for preparing diaminophenothiazinium compounds |
| 04/24/2008 | WO2007146202A3 Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof |
| 04/24/2008 | WO2007144080A3 Combination antidepressants wafer |
| 04/24/2008 | WO2007141657A3 Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation |
| 04/24/2008 | WO2007109799A3 Polymorphs of eszopiclone malate |
| 04/24/2008 | WO2007060342A3 Use of guanabenz and its derivatives for making drugs for treating cystic fibrosis and diseases related to a protein addressing deficiency in the cells |
| 04/24/2008 | US20080097117 chemical intermediates for making antiinflammatory agents treating autoimmune disease; 1-[2-(Fluoren-3-yl)ethyl]-(4-(3-trifluoromethylphenyl)-1,2,3,6-tetrahydropyridine drug |
| 04/24/2008 | US20080097109 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses |
| 04/24/2008 | US20080097102 Aminotetralin-derived urea modulators of vanilloid vr1 receptor |
| 04/24/2008 | US20080097094 cis-6-(3-pyridinyl)-3,6-diazabicyclo[3.2.0]heptane; for controlling synaptic transmission, neurotransmitter release; Alzheimer's disease, Parkinson's disease, attention deficit disorder, depression, nicotinic withdrawal syndrome, Tourette's syndrome, schizophrenia and pain |
| 04/24/2008 | US20080096980 which cause various pathologies including Parkinson's, Huntington's, and Alzheimer's Diseases; agent that induces a survival response by the cell; induces sequestration of toxic protein in an inclusion body; |
| 04/24/2008 | US20080096968 Derivatives of 1-Phenylalkanecarboxylic Acids for the Treatment of Neurodegenerative Diseases |
| 04/24/2008 | US20080096967 Formulations for Injection of Catecholic Butanes, Including Ndga Compounds, Into Animals |
| 04/24/2008 | US20080096949 Indazolyl-substituted pyrroline compounds as kinase inhibitors |
| 04/24/2008 | US20080096942 Beta-secretase inhibitors; use in treating Alzheimer's disease; for example, N-{(1S,2R)-1-[3-(cyclohexylmethyl)benzyl]-2-hydroxy-3-[(3-methoxybenzyl)amino]propyl}acetamide hydrochloride |
| 04/24/2008 | US20080096936 Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them |
| 04/24/2008 | US20080096934 N-[4-((S)-2-Propylamino-propyl)-phenyl]-4-trifluoromethoxy-benzenesulfonamide; Dipropyl-{2-[4-(4-trifluoromethoxy-benzenesulfonylmethyl)-phenyl]-ethyl}-dipropyl-amine salt, psychological, nervous system disorders such as schizophernia, bipolar, dyskinesias, tourette syndrome, depression, sleep disorder |
| 04/24/2008 | US20080096931 fewer side effects; 2-keto-oxadiazole derivatives; 7-phenyl-1-[5-(pyridin-2-yl)-1,3,4-oxadiazol-2-yl]-heptan-1-one; treat anxiety, pain, inflammation, sleep disorders, eating disorders, or movement disorders |
| 04/24/2008 | US20080096930 1-(2-hydroxy-3-methyl-4-{4-[4-(1H-tetrazol-5-yl)-pyridin-2-yloxy]-benzyloxy}-phenyl)-ethanone; 6-(3-((4-acetyl-3-hydroxy-2-propylphenoxy)methyl)phenylthio)isonicotinic acid; 1-(2-hydroxy-4-{3-[4-(2H-tetrazol-5-yl)-pyridin-2-yloxy]-benzyloxy}-3-trifluoromethyl-phenyl)-ethanone; treatment of migriane |
| 04/24/2008 | US20080096926 Treatment Of Cognitive Impairment Using A Selective Dopamine D1 Receptor Agonist |
| 04/24/2008 | US20080096925 Analgesics for neuropathy, surgery, nervous system disorders, headaches, arthritis, psoriasis, respiratory system disorders, and gastrointestinal disorders; ethyl 4-phenyl-4-[1-(phenylmethyl)-1H-imidazol-2-yl]-1-piperidinecarboxylate; |
| 04/24/2008 | US20080096924 (2R) N-(1-benzylpiperidin-4-yl)-3-cyclohexylmethylthio-2-[(4R)-3-tert-butoxycarbonylthiazolidin-4-ylcarbonylamino]propanamide and hydroxypropyl methylcellulose acetate succinate or hydroxypropyl cellulose; N-type calcium channel blockers; analgesics; oral and nasal formulations; storage stability |
| 04/24/2008 | US20080096923 Determining the severity of retinopathy, neuropathy, and nephropathy; administering 8, 16, or 32 mg one to three times per day of ruboxistaurin, enzastaurin, PKC 412, candesartan cilexetil, fidarestat, lidorestat, pyridoxamine, pegaptanib, or ranibizumab |
| 04/24/2008 | US20080096910 Rapid release mini-tablets provide analgesia in laboratory animals |
| 04/24/2008 | US20080096906 good affinity to the trace amine associated receptors (TAARs), especially for TAAR1; (3-Chloro-phenyl)-(1H-imidazol-2-ylmethyl)-methyl-amine from 3-chloro-N-methylaniline and imidazole-2-carboxyaldehyde and reduction of the carbonyl to methylene |
| 04/24/2008 | US20080096901 Aminotriazole compounds useful as inhibitors of protein kinases |
| 04/24/2008 | US20080096891 Triazine derivatives, their preparation and therapeutic application thereof |
| 04/24/2008 | US20080096890 Highly Selective Norepinephrine Reuptake Inhibitors and Methods of Using the Same |
| 04/24/2008 | US20080096888 Novel compounds as opioid receptor modulators |
| 04/24/2008 | US20080096887 Benzene, Pyridine, and Pyridazine Derivatives |
| 04/24/2008 | US20080096885 Methyl 1-(2-fluorophenyl)-2-[(3-methoxy-2-phenylquinolin-4-yl)carbonyl]hydrazinecarboxylate; schizophrenia |
| 04/24/2008 | US20080096882 PDE4 (Phosphodiesterase) inhibitors; respiratory diseases, gastrointestinal diseases, inflammation the joints, skin or eyes, cancers, or diseases of the peripheral or central nervous system |
| 04/24/2008 | US20080096880 Use of imidazo[1,2,4]triazinones which are inhibitors of cGMP-metabolizing phosphodiesterases (PDE I, II and V) to treat cardiovascular disorders, urogenital disorders, prostate hyperplasia, ocular disorders such as glaucoma, optic neuropathy, diabetic gastroparesis, dementia |
| 04/24/2008 | US20080096878 CGRP (Calcitonin Gene-Related Peptide); migraine and cluster headaches; 2-(5-Bromo-1'1'-dioxido-2-oxo-2',3',5',6'-tetrahydrospiro[indole-3,4'-thiopyran]-1 (2H)-yl)-N-(2'-oxo-1,1',2',3-tetrahydrospiro[indene-2,3'-pyrrolo[2,3-b]pyridin]-5-yl)acetamide for example; use with other drugs |
| 04/24/2008 | US20080096876 Histamine receptor antagonists; 4-[3-(4-Piperidin-1-yl-but-1-ynyl)-benzyl]-thiomorpholine; antiallergens, antihistamines, antiepileptic agents; asthma, alzheimer's disease, narcolepsy, motion sickness, attention deficit disorder, schizophrenia |
| 04/24/2008 | US20080096873 New compounds |
| 04/24/2008 | US20080096872 Composition for Treatment of Pain Specification |
| 04/24/2008 | US20080096871 Schizophrenia, bipolar I disorder, agitation, borderline personality disorder; intramuscular sustained release formulations and depots |
| 04/24/2008 | US20080096870 Oral, intranasal or intravenous administration of bromophenylalanine and a neuroleptic agent; NMDA receptor agonists; schizophrenia; anxiolytic agents, antidepressants; Alzheimer's disease; bipolar disorder |
| 04/24/2008 | US20080096867 Imidazo[1,2-A] Pyridine Anxiolytics |
| 04/24/2008 | US20080096827 Formulation Of A Mixture Of Free-B-Ring Flavonoids And Flavans For Use In The Prevention And Treatment Of Cognitive Decline And Age-Related Memory Impairments |
| 04/24/2008 | US20080096826 Formulation Of A Mixture Of Free-B-Ring Flavonoids And Flavans For Use In The Prevention And Treatment Of Cognitive Decline And Age-Related Memory Impairments |
| 04/24/2008 | US20080096825 Preparation and Use of Phlorizin Compositions |
| 04/24/2008 | US20080096822 Use of the Neurotoxic Component of a Botulinum Toxin |
| 04/24/2008 | US20080096818 administering polypeptides comprising beta amyloid fragments, to induce immunogenic response against amyloid deposits; prophylaxios and therapy of Alzheimer's disease |
| 04/24/2008 | US20080096796 Peptides That Stimulate Cell Survival and Axon Regeneration |
| 04/24/2008 | US20080095832 Prosaposin as a neurotrophic factor |
| 04/24/2008 | US20080095821 Peptides and peptide mimetics to treat pathologies characterized by an inflammatory response |
| 04/24/2008 | US20080095788 Vaccines |
| 04/24/2008 | US20080095766 Methods for the Treatment of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies with Reduced Toxicity |
| 04/24/2008 | US20080095762 Glycoprotein compositions |
| 04/24/2008 | US20080095759 Defense and Counter-Defense Compositions and Methods |
| 04/24/2008 | US20080095750 Use of adipose-derived stem cells for treatment of leukodystrophies |
| 04/24/2008 | US20080095749 Mesenchymal stem cells and uses therefor |
| 04/24/2008 | US20080095743 Using immunoglobulins to identify and isolate skeletal-based precursor of cardiomyocytes (Spoc) for use in treatment of nervous system disorders |
| 04/24/2008 | DE102006049527A1 Use of potassium voltage channel 1.5 inhibitors for producing a medicament for the therapy or prophylaxis of e.g. respiratory disorders, upper airway resistance syndrome, neurodegenerative disorders and lung cancer |
| 04/24/2008 | CA2800404A1 Antidepressant, neuroprotectant, amyloid .beta. deposition inhibitor or age retardant containing heterocyclic compound having specific structure |
| 04/24/2008 | CA2800331A1 Antidepressant, neuroprotectant, amyloid .beta. deposition inhibitor or age retardant containing heterocyclic compound having specific structure |
| 04/24/2008 | CA2666934A1 Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor |
| 04/24/2008 | CA2666841A1 Compounds for stimulating p-glycoprotein function and uses thereof |
| 04/24/2008 | CA2666762A1 Aminomethyl-4-imidazoles |
| 04/24/2008 | CA2666647A1 Substituted tetrahydropyrrolopyrazine compounds with affinity for the kcnq2/3 k+ channel and the use thereof in medicaments |
| 04/24/2008 | CA2666590A1 Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors |
| 04/24/2008 | CA2666360A1 An alzheimer's disease progression inhibitor containing heterocyclic compound having specific structure |
| 04/24/2008 | CA2666219A1 Novel anxiolytic compounds |
| 04/24/2008 | CA2665592A1 Compositions and methods for modulating tlr14 activity |
| 04/24/2008 | CA2665381A1 Polymorphs of o-desmethyl venlafaxine succinate |
| 04/24/2008 | CA2665255A1 Aminomethyl-2-imidazoles with affinity with the trace amine associated receptors |
| 04/24/2008 | CA2665204A1 Biphenyl sulfonyl and phenyl-heteroaryl sulfonyl modulators of the histamine h3-receptor useful for the treatment of disorders related thereto |
| 04/23/2008 | EP1914310A2 Cell-permeable peptide inhibitors of the JNK signal transduction pathway |
| 04/23/2008 | EP1914305A1 GSK3 polypeptides |
| 04/23/2008 | EP1914232A1 N-dihydroxyalkyl-substituted 2-oxoimidazole derivative |
| 04/23/2008 | EP1913948A1 Re-epithelializing pharmaceutical compositions containing xanthan gum |
| 04/23/2008 | EP1913938A1 Transdermal buprenorphine dosage regimen for analgesia |
| 04/23/2008 | EP1913017A1 Substituted ethane-1,2-diamines for the treatment of alzheimer's disease ii |
| 04/23/2008 | EP1913001A2 (r)-n-methylnaltrexone, processes for its synthesis and its pharmaceutical use |
| 04/23/2008 | EP1912989A2 Tricyclic benzimidazoles and their use as metabotropic glutamate receptor modulators |
| 04/23/2008 | EP1912983A2 Modulators of cystic fibrosis transmembrane conductance regulator |
| 04/23/2008 | EP1912979A2 Phenyl-3-{(3-(1h-pyrrol-2-yl)-[1,2,4]oxadiazol-5-yl]piperidin-1-yl}-methanone derivatives and related compounds as positive allosteric modulators of metabotropic glutamate receptors |
| 04/23/2008 | EP1912976A1 Indol-3-yl-carbonyl-piperidin-benzoimidazol derivatives as v1a receptor antagonists |
| 04/23/2008 | EP1912967A1 Quinoline derivatives as neurokinin receptor antagonists |
| 04/23/2008 | EP1912954A2 Novel cysteine protease inhibitors and their therapeutic applications |
| 04/23/2008 | EP1912940A1 Substituted isoindolones and their use as metabotropic glutamate receptor potentiators |
| 04/23/2008 | EP1912939A1 Metabotropic glutamate-receptor-potentiating isoindolones |
| 04/23/2008 | EP1912653A2 Heterocyclic benzodiazepine cgrp receptor antagonists |
| 04/23/2008 | EP1912644A2 N-(arylalkyl)-1h-pyrrolopyridine-2-carboxamide derivatives, preparation and use thereof |
| 04/23/2008 | EP1912638A2 Composition of n-3 fatty acids having high concentration of epa and/or dha and containing n-6 fatty acids |
| 04/23/2008 | EP1912637A2 Inhibitors of egln3 activity for the treatment of neurodegenerative disorders |
| 04/23/2008 | EP1802578B1 3,6-substituted 5-arylamino-1h-pyidine-2-one derivatives and related compounds as poly(adp-ribose)polymerase (parp) inhibitors in the treatment of tissue damage or disease caused by necrosis or apoptosis |
| 04/23/2008 | EP1689493A4 Calcitonin gene related peptide receptor antagonists |
| 04/23/2008 | EP1635828B1 4-(2-phenyloxyphenyl)-piperidine or -1,2,3,6-tetrahydropyridine derivatives as serotonin reuptake inhibitors |
| 04/23/2008 | EP1615896B1 Novel benzimidazole derivatives and pharmaceutical compositions comprising these compounds |